Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $9.3 million.

  • bioAffinity Technologies' Cash from Financing Activities rose 45815.4% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.4 million, marking a year-over-year increase of 33844.1%. This contributed to the annual value of $5.6 million for FY2024, which is 173126.38% up from last year.
  • As of Q3 2025, bioAffinity Technologies' Cash from Financing Activities stood at $9.3 million, which was up 45815.4% from $3.0 million recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' Cash from Financing Activities peaked at $15.0 million during Q3 2022, and registered a low of -$563556.0 during Q4 2022.
  • In the last 4 years, bioAffinity Technologies' Cash from Financing Activities had a median value of $301363.0 in 2022 and averaged $2.2 million.
  • As far as peak fluctuations go, bioAffinity Technologies' Cash from Financing Activities crashed by 12764.64% in 2023, and later skyrocketed by 341207.98% in 2025.
  • bioAffinity Technologies' Cash from Financing Activities (Quarter) stood at -$563556.0 in 2022, then soared by 84.95% to -$84805.0 in 2023, then surged by 2488.86% to $2.0 million in 2024, then soared by 361.18% to $9.3 million in 2025.
  • Its last three reported values are $9.3 million in Q3 2025, $3.0 million for Q2 2025, and $1.0 million during Q1 2025.